All change
Tim Tyson, currently president, global manufacturing & supply, is leaving GlaxoSmithKline (GSK) to take up a new position as president and coo for ICN Pharmaceuticals, a research-based specialty pharmaceuticals company, based in Costa Mesa, California.
Dr David Pulman, currently senior vp - strategy, logistics & north American supply, global manufacturing & supply, GSK, will replace him and will report to Robert Ingram, until Ingram's retirement on 31 December 2002.
Subsequently he will report to David Stout, who assumes the role of president, pharmaceuticals operations, from January 2003. Dr Pulman will be based in Research Triangle Park, North Carolina, US.
Bristol-Myers Squibb has named Dr James B. D. Palmer to succeed Dr Peter Ringrose as chief scientific officer (cso) responsible for the company's worldwide pharmaceutical r&d operations with immediate effect. Dr. Palmer joins the company from GSK, where he was senior vice president for new product development.
'Dr Palmer's r&d acumen and commercial orientation will be a great asset as we continue to manage our development portfolio,' said Peter R. Dolan, chairman and ceo for B-MS.
Inoxell, the Danish drug discovery company spun out of Pharmexa in July 2001, is losing both its ceo and its cso. The ceo Peter Kristensen and cso Jacob Sten Petersen both joined Inoxell from Novo Nordisk when Inoxell was formed and are now returning to Novo Nordisk.
The resignations leave Pharmexa and Inoxell with an urgent problem, according to Soren Mouritsen, ceo of Pharmexa and chairman of the board of directors at Inoxell.
'Unfortunately the financing climate in the biotech industry is such that job security has become an important parameter, and here the larger companies currently have the best offers,' he said.
'Fortunately the organisation in Inoxell is strong and the company's activities will continue as before. We have previously stated that we must find a solution for Inoxell's future and we are still working on a number of options.'